Forbion Capital Partners

eeden is a recycling technology company focused on advancing textile recycling through its patented chemical process. The company addresses the significant challenge of efficiently recovering cellulose and polyester from polycotton blends, facilitating the production of high-quality clothing without relying on virgin resources. By extracting these materials, eeden enables brands to reduce textile waste and lessens their environmental impact, helping them comply with global regulations. The company's innovative approach not only contributes to the sustainable recycling of clothing but also supports the broader shift toward a circular economy in the apparel industry, promoting the repurposing of textile waste into new products.

Granite Bio is a biotechnology company that specializes in the development of novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company's primary focus is on creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological pathways associated with these diseases. By advancing innovative antibody treatments, Granite Bio aims to contribute significantly to the fields of biotechnology and pharmaceuticals, addressing critical needs in the life sciences sector.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Verdiva Bio is a biopharmaceutical company specializing in the development of innovative therapies for patients with obesity and cardiometabolic disorders. The company focuses on creating more patient-friendly treatment options by targeting gut-brain biology, with a pipeline centered around multiple amylin molecules. This approach aims to enhance efficacy, improve tolerability, and facilitate healthier weight loss for individuals facing these health challenges.

Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.

Orbis Medicines is a biotechnology company focused on advancing drug discovery through its innovative macrocyclic chemistry and computational platform. The company specializes in high-throughput drug discovery, aiming to develop new therapeutics that can significantly improve patient outcomes. By leveraging its unique chemistry and advanced computational techniques, Orbis Medicines seeks to address challenging targets in areas with high unmet medical needs, thereby accelerating the process of bringing effective treatments to market.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

SynOx Therapeutics is a clinical stage biopharmaceutical company based in Dublin, Ireland, established in 2019. The company focuses on the development of innovative therapies for cancer, particularly through its lead product, emactuzumab. This humanized monoclonal antibody specifically targets the CSF-1 receptor, aiming to deplete macrophages within tumor tissues. SynOx Therapeutics is dedicated to addressing the unmet clinical needs of patients suffering from diffuse tenosynovial giant cell tumors and other conditions associated with macrophage activity, ultimately striving to provide best-in-class treatment options that enhance patient quality of life. The company is backed by experienced investors with a strong track record in biopharmaceutical development.

enGene, Inc. is a biotechnology company based in Vancouver, Canada, specializing in mucosal immunotherapy to address inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables the localized delivery of immune-modulating proteins to mucosal tissues, targeting conditions affecting the gastrointestinal tract, lung, and bladder. This innovative platform allows for the systemic release of proteins from the gut, which can be beneficial for treating a variety of immune disorders, as well as other conditions such as diabetes, anemia, and hemophilia. Founded in 1999, enGene has formed a strategic alliance with Takeda Pharmaceutical Company to further advance its therapeutic offerings.

Purespring Therapeutics is a biotechnology company specializing in the development of gene therapies for various kidney diseases. It focuses on targeting podocytes, specialized cells within the kidneys, using adeno-associated virus (AAV) vectors. The company aims to address unmet needs in renal conditions and has established an in-vivo functional screening platform to identify protective factors that could potentially benefit multiple kidney diseases.

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Novameat is a company focused on developing advanced technological solutions for creating plant-based meat substitutes. By addressing the inefficiencies and unsustainability of traditional animal agriculture, Novameat aims to provide a healthy, humane, and environmentally sustainable food supply. The company's proprietary micro-extrusion technology enables the production of plant-based products that closely replicate the texture, appearance, taste, and nutritional qualities of various animal meats, including beef steaks. This innovation seeks to meet the demands of the growing global population while offering affordable, vegan alternatives for consumers. Novameat has garnered media attention from major outlets, highlighting its role in the evolving landscape of food technology.

Solasta Bio focuses on developing environmentally friendly products that address the global demand for innovative and effective crop protection. The company creates biological pesticides and neuropeptide-based insect control solutions designed to provide superior natural protection for crops. Its product portfolio encompasses a wide range of offerings that target various pests, including those that have developed resistance to traditional synthetic chemicals. By enabling farmers to manage pest populations sustainably, Solasta Bio aims to enhance crop production while prioritizing safety and environmental responsibility.

Navigator Medicines is a biotechnology company dedicated to advancing biologics for targeted immune regulation and restoration. It focuses on developing treatments for complex autoimmune diseases, aiming to improve patient care and outcomes.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

Pheon Therapeutics is a London-based biotechnology company specializing in the development of Antibody-Drug Conjugates (ADCs) for challenging cancer types. Founded in 2022, the company focuses on creating a novel pipeline of next-generation ADCs designed to target solid tumors that are often resistant to existing treatments. Its lead program features a first-in-class ADC aimed at a unique target that is highly expressed in various hard-to-treat cancers. By advancing these innovative therapies, Pheon Therapeutics aims to provide effective treatment options for patients and healthcare providers facing the complexities of cancer management.

Progentos Therapeutics is a biopharmaceutical company focused on developing innovative therapies for chronic diseases, specifically targeting multiple sclerosis. The company has created novel small-molecule therapeutics aimed at activating oligodendrocyte progenitor cells, which play a crucial role in myelin regeneration. By stimulating the body's natural repair mechanisms, Progentos Therapeutics seeks to help patients recover lost functions and enhance their quality of life. Through its research and development efforts, the company is committed to addressing the unmet medical needs of those affected by multiple sclerosis.

Seamless Therapeutics is a biotechnology company focused on advancing gene editing through its innovative technology platform, which specializes in the reprogramming of recombinases, a versatile class of enzymes. The company aims to transform the treatment landscape for patients with severe health conditions by providing disease-modifying product candidates that enhance the safety and precision of gene editing. By leveraging its unique approach, Seamless Therapeutics seeks to unlock new therapeutic potentials, ultimately striving to restore health and improve patient outcomes.

SynOx Therapeutics is a clinical stage biopharmaceutical company based in Dublin, Ireland, established in 2019. The company focuses on the development of innovative therapies for cancer, particularly through its lead product, emactuzumab. This humanized monoclonal antibody specifically targets the CSF-1 receptor, aiming to deplete macrophages within tumor tissues. SynOx Therapeutics is dedicated to addressing the unmet clinical needs of patients suffering from diffuse tenosynovial giant cell tumors and other conditions associated with macrophage activity, ultimately striving to provide best-in-class treatment options that enhance patient quality of life. The company is backed by experienced investors with a strong track record in biopharmaceutical development.

Engrail Therapeutics, Inc. is dedicated to developing and commercializing neuro drugs aimed at treating diseases of the nervous system. Founded in 2019 and based in San Diego, California, the company focuses on creating transformative medicines to alleviate the significant burden of such conditions. One of its key products is ENX-101, a preclinical compound designed to modulate a receptor for GABA, a critical neurotransmitter in the brain. Engrail Therapeutics combines biological insights with clinically meaningful solutions to advance its portfolio of therapies, utilizing a flexible transaction model to efficiently progress its drug candidates from development to commercialization.

Orbis Medicines is a biotechnology company focused on advancing drug discovery through its innovative macrocyclic chemistry and computational platform. The company specializes in high-throughput drug discovery, aiming to develop new therapeutics that can significantly improve patient outcomes. By leveraging its unique chemistry and advanced computational techniques, Orbis Medicines seeks to address challenging targets in areas with high unmet medical needs, thereby accelerating the process of bringing effective treatments to market.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Calluna Pharma is a clinical-stage company focused on developing innovative therapies that leverage the body's immune system to treat various immunological diseases. The company has established a strong pipeline of selective antibodies aimed at addressing unmet clinical needs across a range of conditions. Its approach includes precision targeting of upstream innate immune amplifiers and the disruption of disease-associated downstream signaling pathways, all while ensuring a favorable safety profile for its therapeutic candidates. Through its research and development efforts, Calluna Pharma aims to transform treatment options for patients suffering from immunological disorders.

Kynexis is focused on developing a precision medicine aimed at treating cognitive impairment associated with schizophrenia. The company employs a human biology-based approach to guide its research, utilizing a causal biomarker strategy to clarify its mechanism of action during clinical development. Additionally, Kynexis incorporates a human genetics approach to identify specific sub-populations of patients who are likely to respond positively to the treatment. Through its innovative methodologies, Kynexis aims to enhance brain function in individuals suffering from schizophrenia, addressing a critical need in mental health care.

Aiolos Bio is a biotechnology company specializing in the development of therapies for respiratory diseases and immune conditions. Its primary focus is on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma, designed for dosing every 6 months. The company, founded by industry veterans, aims to address unmet treatment needs and improve patient outcomes by providing more efficacious and less burdensome therapies.

Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It employs proprietary development and delivery platforms to create optimized therapeutics in a revocable, non-viral format, advancing gene-based therapies with improved safety and controllability. The company integrates capabilities from gene delivery, protein sciences, and clinical translation to address genetically driven diseases and translate scientific advances into clinical options.

Tessellate BIO is a biotechnology company focused on oncology, developing precision therapies that leverage synthetic lethality to treat cancers with significant unmet medical needs. It targets tumors dependent on synthetic lethality mechanisms to create targeted treatments, supported by ongoing research and development in cancer biology and pharmaceutical processes.

Mariana Oncology is a biotechnology company focused on developing innovative radiopharmaceuticals aimed at targeting cancer cells with radioactive drugs. The company employs a multidisciplinary approach that includes ligand discovery, radiochemistry, radiobiology, and translational and clinical research in oncology. By building a diverse pipeline of treatments for various solid tumor types, Mariana Oncology seeks to enhance the efficacy of radio medicines in cancer therapy, ultimately aiding medical professionals in their efforts to improve patient outcomes.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations of traditional AAV vectors, particularly in terms of cargo capacity. This innovative approach allows for the delivery of large genes to both ocular and non-ocular tissues, facilitating effective in vivo treatment options for patients suffering from these conditions. Through its advanced technology, AAVantgarde Bio aims to enhance therapeutic outcomes and improve the quality of life for individuals affected by genetic eye diseases.

Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.

Complement Therapeutics is a preclinical stage biotechnology company focused on addressing chronic diseases linked to the dysregulation of the complement system. The company has developed a precision medicine diagnostic platform that stratifies patients according to their complement-activation profiles. This innovative approach not only facilitates patient selection for future clinical trials but also serves as an efficacy biomarker, potentially enhancing medical treatment outcomes. By leveraging its platform methodology, Complement Therapeutics aims to improve the precision of treatments for patients suffering from conditions influenced by complement system dysregulation.

Seamless Therapeutics is a biotechnology company focused on advancing gene editing through its innovative technology platform, which specializes in the reprogramming of recombinases, a versatile class of enzymes. The company aims to transform the treatment landscape for patients with severe health conditions by providing disease-modifying product candidates that enhance the safety and precision of gene editing. By leveraging its unique approach, Seamless Therapeutics seeks to unlock new therapeutic potentials, ultimately striving to restore health and improve patient outcomes.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Pheon Therapeutics is a London-based biotechnology company specializing in the development of Antibody-Drug Conjugates (ADCs) for challenging cancer types. Founded in 2022, the company focuses on creating a novel pipeline of next-generation ADCs designed to target solid tumors that are often resistant to existing treatments. Its lead program features a first-in-class ADC aimed at a unique target that is highly expressed in various hard-to-treat cancers. By advancing these innovative therapies, Pheon Therapeutics aims to provide effective treatment options for patients and healthcare providers facing the complexities of cancer management.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

Complement Therapeutics is a preclinical stage biotechnology company focused on addressing chronic diseases linked to the dysregulation of the complement system. The company has developed a precision medicine diagnostic platform that stratifies patients according to their complement-activation profiles. This innovative approach not only facilitates patient selection for future clinical trials but also serves as an efficacy biomarker, potentially enhancing medical treatment outcomes. By leveraging its platform methodology, Complement Therapeutics aims to improve the precision of treatments for patients suffering from conditions influenced by complement system dysregulation.

Armgo Pharma, Inc. is a biopharmaceutical company focused on developing small-molecule therapeutics aimed at treating debilitating cardiac, skeletal muscular, and neurological disorders. The company specializes in Rycals, which are innovative calcium release channel stabilizers that target the ryanodine receptor/calcium release channel located on the sarcoplasmic/endoplasmic reticulum of cells. These therapeutics are designed to address various conditions, including chronic heart failure, cardiac arrhythmias, muscle disorders, cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. Incorporated in 2004, Armgo Pharma is headquartered in Tarrytown, New York, with an additional office in New York City.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in the development of biologics aimed at modulating cytokine functions to provide therapeutic benefits for patients with immune pathology. Anaveon focuses on creating next-generation IL-2-based therapeutic antibodies that selectively enhance effector T cell functions, thereby acting as effective immune adjuvants. Its compounds demonstrate substantial preclinical efficacy against cancer, both as monotherapy and in combination with other treatments. Through these advancements, Anaveon aims to transform cytokines into life-saving treatments for various diseases associated with immune system dysfunction.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

Rectify Pharmaceuticals is focused on creating disease-modifying precision therapies aimed at addressing the root causes of serious genetic diseases. The company specializes in developing positive functional modulators (PFMs) that restore the function of ABC transporters, which are critical for cellular processes. By targeting these underlying mechanisms, Rectify aims to provide innovative treatment solutions that improve the health outcomes of patients suffering from various genetic conditions. Their research and development efforts encompass multiple therapeutic areas, reflecting a commitment to advancing precision medicine in the field of genetic disorders.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Amphista Therapeutics Limited is a biopharmaceutical company founded in 2017 and located in Motherwell, United Kingdom. It specializes in developing targeted protein degradation technology aimed at creating innovative cancer therapeutics. The company focuses on harnessing the body's natural processes to selectively degrade and eliminate disease-causing proteins. By advancing next-generation therapeutics, Amphista seeks to improve treatment efficacy for various diseases, particularly cancer, by modulating the abundance of proteins responsible for disease progression. This strategic approach aims to enhance patient outcomes and contribute to the advancement of therapeutic options in oncology.

Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments aimed at addressing various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technologies designed to enhance the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular aims to improve patient outcomes, reduce side effects, and decrease the frequency of treatments required. The company is committed to transforming the landscape of retinal therapeutics and providing life-changing solutions for patients facing unmet medical needs.

CoviCept Therapeutics is focused on the development of a small molecule that inhibits the replication and spread of RNA viruses.

Complement Therapeutics is a preclinical stage biotechnology company focused on addressing chronic diseases linked to the dysregulation of the complement system. The company has developed a precision medicine diagnostic platform that stratifies patients according to their complement-activation profiles. This innovative approach not only facilitates patient selection for future clinical trials but also serves as an efficacy biomarker, potentially enhancing medical treatment outcomes. By leveraging its platform methodology, Complement Therapeutics aims to improve the precision of treatments for patients suffering from conditions influenced by complement system dysregulation.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

SynOx Therapeutics is a clinical stage biopharmaceutical company based in Dublin, Ireland, established in 2019. The company focuses on the development of innovative therapies for cancer, particularly through its lead product, emactuzumab. This humanized monoclonal antibody specifically targets the CSF-1 receptor, aiming to deplete macrophages within tumor tissues. SynOx Therapeutics is dedicated to addressing the unmet clinical needs of patients suffering from diffuse tenosynovial giant cell tumors and other conditions associated with macrophage activity, ultimately striving to provide best-in-class treatment options that enhance patient quality of life. The company is backed by experienced investors with a strong track record in biopharmaceutical development.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven neuromuscular diseases. It aims to deliver disease-modifying therapeutics to skeletal, cardiac, and smooth muscle, addressing conditions such as muscular dystrophies and other muscle disorders. The company uses the FORCE platform to create targeted therapeutics with payloads designed to address the disease gene, connected via a linker to an antigen-binding fragment, enabling delivery to muscle tissue and the central nervous system. Its pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. Headquartered in Waltham, Massachusetts.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Azafaros B.V., based in Leiden, the Netherlands, specializes in the development of therapeutic agents aimed at treating rare metabolic disorders, specifically lysosomal storage disorders. The company focuses on innovative oral medications made from aza-sugar compounds, which were originally discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC, and have been exclusively licensed to Azafaros. These promising therapeutic agents are designed to address critical disease pathways by targeting the central nervous system and altering the metabolism of glycosphingolipids through a unique dual mode of action. Azafaros seeks to improve patient outcomes and enhance the quality of life for individuals affected by these severe inherited conditions.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

SANIFIT is a biotechnology company developing treatments for calcification disorders, including progressive vascular calcification and cardiovascular diseases linked to calcification in patients with end-stage renal disease on hemodialysis. It operates as a clinical-stage biopharmaceutical company focused on therapies to prevent or treat calcium-related pathologies that contribute to heart disease in dialysis patients.

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven neuromuscular diseases. It aims to deliver disease-modifying therapeutics to skeletal, cardiac, and smooth muscle, addressing conditions such as muscular dystrophies and other muscle disorders. The company uses the FORCE platform to create targeted therapeutics with payloads designed to address the disease gene, connected via a linker to an antigen-binding fragment, enabling delivery to muscle tissue and the central nervous system. Its pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. Headquartered in Waltham, Massachusetts.

Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, established in 2016. The company specializes in developing orally available drugs aimed at addressing unmet clinical needs in inflammatory diseases by targeting inflammasomes, which are critical in the inflammatory process. Inflazome's innovative therapies are designed to block inflammasome signals, thereby addressing the root causes of inflammation. The company's portfolio includes treatments for a range of conditions, such as neurological disorders like Alzheimer's and Parkinson's, systemic inflammatory diseases, and certain orphan diseases. As of September 2020, Inflazome operates as a subsidiary of Roche Holding AG, further enhancing its capacity to deliver targeted therapies in the field of inflammatory diseases.

OMEICOS Therapeutics is a Berlin-based biotechnology company developing small molecule therapeutics to prevent and treat cardiovascular and ophthalmic diseases. The company uses synthetic analogues of Epoxyeicosanoids, metabolites of omega-3 fatty acids, to activate anti-inflammatory, anti-arrhythmic, and cardioprotective pathways in heart cells. Its approach leverages endogenous cardio-protective signaling to stabilize heart rhythm and potentially mitigate electrical and structural remodeling of diseased myocardium.

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing etripamil, a rapid-onset calcium channel blocker for cardiovascular conditions. The lead product is etripamil, administered as a nasal spray for self-treatment of episodes of paroxysmal supraventricular tachycardia, with ongoing Phase III studies in the United States and Canada. The company is also advancing development for other cardiovascular indications, including atrial fibrillation and angina, with a Phase II program for atrial fibrillation with rapid ventricular response. Founded in 2003, Milestone is headquartered in Montreal.

Gotham Therapeutics Corp. is a biotechnology company based in New York, founded in 2017, that focuses on developing innovative treatments for patients with cancers, autoimmune disorders, and neurodegenerative diseases. The company specializes in a novel class of drugs that target the machinery of epitranscriptomics, which involves altering the activity of proteins that modify messenger ribonucleic acid (mRNA). By utilizing small molecules that inhibit the transcription of proteins through modifications to mRNA, Gotham Therapeutics aims to enhance treatment options and improve outcomes for individuals affected by serious health conditions.

KaNDy Therapeutics is a biopharmaceutical company specializing in the development of non-hormonal treatments for various symptoms associated with menopause, including hot flashes and nighttime awakenings. Founded in 2017 and based in Stevenage, United Kingdom, the company focuses on providing effective therapies for moderate to severe post-menopausal vasomotor symptoms. Its lead product, NT-814, addresses chronic debilitating conditions related to female sex hormones, offering a viable alternative for patients seeking relief without hormonal interventions. As a subsidiary of Bayer Aktiengesellschaft, KaNDy Therapeutics aims to improve the quality of life for women experiencing hormone-related challenges.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Escalier Biosciences B.V. is a biopharmaceutical company based in Nijmegen, the Netherlands, specializing in the development of small molecule therapeutics aimed at treating autoimmune disorders, particularly psoriasis. Founded in 2016, the company is engaged in creating innovative drug candidates that effectively target ROR?t, a critical regulator in the inflammatory process. Escalier's lead products, which are designed for both topical and oral administration, are currently in late-stage preclinical studies. These therapeutics are formulated to enhance penetration in dermal tissues, thereby maximizing target engagement at sites of inflammation while minimizing systemic drug activity and associated side effects. In addition to its operations in the Netherlands, Escalier has an office in Encinitas, California.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

Replimune Group, Inc., established in 2015 and based in Woburn, Massachusetts, is a biotechnology company specializing in the development of oncolytic immune-gene therapies for cancer treatment. The company's proprietary Immulytic platform enables the design of product candidates that directly attack cancer cells and stimulate the immune system. Replimune's lead candidate, RP1, is a modified herpes simplex virus currently in Phase I/II trials for various solid tumors and Phase II trials for cutaneous squamous cell carcinoma. Additionally, RP2 and RP3 are in early-stage clinical trials, targeting immune checkpoint inhibition and T-cell stimulation, respectively. Replimune aims to rapidly advance these therapies through clinical trials and explore combinations with other immuno-oncology products.

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing etripamil, a rapid-onset calcium channel blocker for cardiovascular conditions. The lead product is etripamil, administered as a nasal spray for self-treatment of episodes of paroxysmal supraventricular tachycardia, with ongoing Phase III studies in the United States and Canada. The company is also advancing development for other cardiovascular indications, including atrial fibrillation and angina, with a Phase II program for atrial fibrillation with rapid ventricular response. Founded in 2003, Milestone is headquartered in Montreal.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Prexton Therapeutics SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It specializes in the development of innovative drugs for Parkinson's disease and other brain disorders. The company focuses on targeting metabotropic glutamate receptors, specifically mGluR4 and mGluR3, utilizing a novel scientific approach that integrates molecular, behavioral, and chemical technologies. Prexton Therapeutics aims to improve the quality of life for patients by offering alternatives to traditional dopaminergic treatments through its unique mGluR4 PAM series. This approach allows for quicker initiation of treatment, potentially leading to better medical outcomes for individuals suffering from these conditions.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Allecra Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat Gram-negative multi-drug resistant bacterial infections. Founded in 2013 and based in Weil am Rhein, Germany, it develops beta-lactamase inhibitors to counter resistance mechanisms in hard-to-treat bacteria, particularly those linked with hospital-acquired infections. Its beta-lactamase inhibitor program aims to restore the activity of beta-lactam antibiotics against resistant pathogens, with a beta-lactamase inhibitor in Phase 2 development. The company operates in the BioValley Life Sciences region of the Upper Rhine valley, spanning parts of Switzerland, Germany, and France, to advance research and clinical development and improve outcomes for patients and healthcare systems facing resistant infections.

Akarna Therapeutics Ltd. is a biopharmaceutical company focused on developing small molecule therapeutics for inflammatory and fibrotic diseases. Established in 2014, the company operates out of offices in Cambridge, United Kingdom, and San Diego, California. Akarna's lead program centers on a non-bile acid FXR agonist, which aims to provide a best-in-class therapeutic option for treating nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease with no currently approved treatments. At present, the lead candidate is undergoing preclinical studies, including IND-enabling toxicology and safety pharmacology assessments, with plans to initiate first-in-human trials.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Replimune Group, Inc., established in 2015 and based in Woburn, Massachusetts, is a biotechnology company specializing in the development of oncolytic immune-gene therapies for cancer treatment. The company's proprietary Immulytic platform enables the design of product candidates that directly attack cancer cells and stimulate the immune system. Replimune's lead candidate, RP1, is a modified herpes simplex virus currently in Phase I/II trials for various solid tumors and Phase II trials for cutaneous squamous cell carcinoma. Additionally, RP2 and RP3 are in early-stage clinical trials, targeting immune checkpoint inhibition and T-cell stimulation, respectively. Replimune aims to rapidly advance these therapies through clinical trials and explore combinations with other immuno-oncology products.

SANIFIT is a biotechnology company developing treatments for calcification disorders, including progressive vascular calcification and cardiovascular diseases linked to calcification in patients with end-stage renal disease on hemodialysis. It operates as a clinical-stage biopharmaceutical company focused on therapies to prevent or treat calcium-related pathologies that contribute to heart disease in dialysis patients.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Replimune Group, Inc., established in 2015 and based in Woburn, Massachusetts, is a biotechnology company specializing in the development of oncolytic immune-gene therapies for cancer treatment. The company's proprietary Immulytic platform enables the design of product candidates that directly attack cancer cells and stimulate the immune system. Replimune's lead candidate, RP1, is a modified herpes simplex virus currently in Phase I/II trials for various solid tumors and Phase II trials for cutaneous squamous cell carcinoma. Additionally, RP2 and RP3 are in early-stage clinical trials, targeting immune checkpoint inhibition and T-cell stimulation, respectively. Replimune aims to rapidly advance these therapies through clinical trials and explore combinations with other immuno-oncology products.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

Insmed Incorporated is a global biopharmaceutical company dedicated to improving the lives of patients with serious and rare diseases. Its flagship product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the United States for treating Mycobacterium avium complex (MAC) lung disease, targeting adult patients who have limited or no alternative treatment options. MAC lung disease is a rare and potentially fatal infection that can lead to significant lung damage. In addition to ARIKAYCE, Insmed's clinical pipeline features Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which shows promise for treating non-cystic fibrosis bronchiectasis and other inflammatory conditions. Another candidate in development is INS1009, an inhaled formulation of a treprostinil prodrug aimed at addressing rare pulmonary disorders, including pulmonary arterial hypertension.